pdufa.bio
CalendarDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › PDUFA Calendar › NVS

NVS PDUFA Date: Pluvicto (lutetium (177Lu) vipivotide tetraxetan)

FDA decision (PDUFA) target 2026-12-31 · Novartis AG · End-stage prostate cancer

NVS run-up into the PDUFA (last ~120 days)

$168.62$142.94
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-12-31
Drug / candidatePluvicto (lutetium (177Lu) vipivotide tetraxetan)
IndicationEnd-stage prostate cancer
CompanyNovartis AG
Market-cap tierLarge
Cohort decision-day move (history)±1% median
ClinicalTrials.govNCT04720157 · nan

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the NVS PDUFA date?
The FDA PDUFA target date for NVS (Novartis AG) is 2026-12-31 for Pluvicto (lutetium (177Lu) vipivotide tetraxetan). Dates are company/FDA-sourced and can slip — verify against primary filings.
What is NVS's drug Pluvicto (lutetium (177Lu) vipivotide tetraxetan)?
Pluvicto (lutetium (177Lu) vipivotide tetraxetan) is Novartis AG's candidate under FDA review for End-stage prostate cancer.
What typically happens to a large-cap stock into a PDUFA date?
Historically, large-cap names had a median decision-day move around ±1% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.